Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Gastroenterology | Infections | Internal Medicine | Critical Care | Nursing | Pharmacy | Journal

Back to Journal Articles

IL-2 Tied to Regulatory T-Cell Expansion in Graft-Versus-Host

Last Updated: November 30, 2011.

 

And, IL-2 associated with Treg recovery and clinical improvement in HCV-induced vasculitis

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Daily low-dose interleukin-2 is safe and induces regulatory T cell expansion with suppression of clinical manifestations in patients with chronic graft-versus-host disease, and is also associated with regulatory T recovery and clinical improvement in patients with hepatitis C virus-induced vasculitis, according to two studies published in the Dec. 1 issue of the New England Journal of Medicine.

WEDNESDAY, Nov. 30 (HealthDay News) -- Daily low-dose interleukin-2 is safe and induces regulatory T (Treg) cell expansion with suppression of clinical manifestations in patients with chronic graft-versus-host disease (GVHD), and is also associated with Treg recovery and clinical improvement in patients with hepatitis C virus (HCV)-induced vasculitis, according to two studies published in the Dec. 1 issue of the New England Journal of Medicine.

John Koreth, M.B., B.S., D.Phil., from the Dana-Farber Cancer Institute in Boston, and colleagues investigated whether low-dose interleukin-2 enhanced Treg cells in vivo and suppressed clinical manifestations in 29 patients with chronic GVHD. No patient showed chronic GVHD progression or relapse of a hematologic cancer. Major responses involving multiple sites were seen in 12 of 23 patients evaluated for response. All patients showed a preferential increase of CD4+ Treg cells, with a peak median increase of more than eight times the baseline value, and no affect on CD4+ conventional T (Tcon) cells. The median Treg:Tcon ratio increased to more than five times the baseline values. These responses were sustained at eight weeks.

David Saadoun, M.D., Ph.D., from the Université Pierre et Marie Curie in Paris, and colleagues investigated the safety and immunologic effects of low-dose interleukin-2 in 10 patients with HCV-induced vasculitis. There were no adverse events higher than grade 1. Treatment was associated with reduced cryoglobulinemia; improved vasculitis; increased percentage of CD4+, CD25high, and forkhead box P3 Tregs with potent suppressive activity; and a concomitant reduction in the proportion of marginal-zone B cells.

Low-dose interleukin-2 was not associated with adverse effects and led to Treg recovery and concomitant clinical improvement," Saadoun and colleagues write.

The Koreth study was funded by a Dana-Farber Dunkin' Donuts Rising Star award. Interleukin-2 used in Koreth's study was donated by Novartis and Prometheus Laboratories.

Full Text - Koreth (subscription or payment may be required)
Full Text - Saadoun (subscription or payment may be required)

Copyright © 2011 HealthDay. All rights reserved.


Previous: Metal, Ceramics on Par With Traditional Hip Implants Next: November 2011 Briefing - Allergy

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.